PE
STLN

Point72 Europe’s Starling Oncology STLN Stock Holding History

Point72 Europe’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$12.5K Buy
+3,572
New +$12.2K ﹤0.01% 515

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Point72 Europe's STLN Position: Q3 2025 in Review

Point72 Europe opened a new position in Starling Oncology (STLN) in Q3 2025: 3,572 shares worth $12.5K. The stake represents ﹤0.01% of the portfolio and ranks #515 among its holdings.

108 funds tracked by Wall St. Rank hold STLN as of Q3 2025.

  • Point72 Europe held 3,572 shares of Starling Oncology worth $12.5K as of Q3 2025.
  • Starling Oncology was a new Point72 Europe position in Q3 2025.
  • Starling Oncology made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #515 holding.
  • 108 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.